“a favorable trend”

In the T2DM subgroup (n = 121), genotype incorporation led to small but statistically significant improvements in discrimination for NFS (AUROC increase: 0.053, p = 0.001) and FIB-4 (AUROC increase: 0.058, p = 0.010), while Agile 3+ showed a favorable trend (AUROC increase: 0.016, p = 0.058).

A favorable trend was noted regarding mortality at 1 year for consultant-led operations vs nonconsultant-led operations (22.1% vs 27.9%, respectively; P =0.058).

A favorable trend was also observed for overall survival (OS) (HR = 0.75, 95% CI: 0.55-1.01, P = 0.059, Figure 3F ), although this did not reach statistical significance.

On univariate analysis, ICI+COXi was not associated with a significant increase in TTP, though there was again a favorable trend (HR 0.48, 95% CI 0.23 to 1.03; p=0.059) ( table 2 ).

Although the percentage of patients achieving ≥75% reduction in PASI showed a favorable trend in the probiotic group (33.57% vs. 23.61%), this difference did not reach statistical significance (RR 1.40; 95% CI: 0.98–1.98; p = 0.06).

PFS and OS in the Evaluable Cohort In the evaluable cohort, PFS12 was higher in the experimental arm compared with the control arm (37.5% vs 17.3%), showing a favorable trend that did not reach statistical significance ( P = .06).

No significant favorable effect of screening was detected, although there was a favorable trend for non-fatal MI (RR = 0.61 [0.29 to 1.29], p = 0.20), and an adverse trend for stroke (RR = 2.11 [0.96 to 4.64], p = 0.06).

Importantly, post‐NAT patients with more fibrosis had longer overall survival ( p = 0.02), and higher B‐cell density showed a favorable trend ( p = 0.06).

BCVA showed a favorable trend in the SGLT2i group, from 0.26 ± 0.25 to 0.18 ± 0.23 by week 48 ( p = 0.06) (Figure 1E ).

−10.69 [95% CI; −27.07 to 5.69]; p = 0.83); however, the high-dose group showed a favorable trend compared with the placebo group (−12.20 vs . −29.32 [95% CI; −53.4 to −5.2]; p = 0.06).

There was a favorable trend towards reduced progression to IMV or ECMO (OR 0.76, 95% CI 0.58-1.01; p=0.06, I 2 =49%) in the baricitinib arm compared to standard therapy, even though it was not statistically significant.

ATRX gene conservation showed a favorable trend in terms of OS despite a significant result was not reached ( p = 0.06; median OS of 11 months vs. 29 months, respectively for ATRX positive vs. negative; HR 2.69, 95% CI 0.92–7.83).

AUC for CLEOS (0.72, 95% CI 0.62–0.81) was statistically superior to PRE (AUC 0.61, 95% CI 0.51–0.71; p = 0.0197), THRIVE (AUC 0.58, 95% CI 0.47–0.69; p<0.001), and SPAN-100 (AUC 0.54, 95% CI 0.48–0.60; p<0.001), and a favorable trend was observed compared to HIAT-2 (AUC 0.63, 95% CI 0.53–0.73; p = 0.0616) for predicting 90-day mRS 4–6 ( Fig 2 ).

In the first IC cycle, the rates were 14.5% versus 22.0% ( p = 0.045), and in the first CCRT cycle, a favorable trend was observed (18.2% vs. 25.7%, p = 0.062).

Early ESCC stage is a predictive makers of better prognosis (P = 0.044) and early HNSCC stage had a favorable trend toward prolonged survival (P = 0.062) in our study.

Compared with participants who consumed citrus </=2 times/week, the multivariate HR (hazard ratio, i.e., the risk related to those with low baseline citrus intake) for dementia among those who ate citrus 3–4 times/week and almost daily was 0.92 (95% CI 0.80–1.07) and 0.86 (95% CI 0.73–1.01), respectively, with a favorable trend ( p = 0.065).

Impact of type of organ-specific irAEs on survival Cutaneous irAEs were associated with a favorable trend toward improved PFS and OS (p=0.065), especially in the higher-line group.

Cox regression demonstrated a favorable trend for the combination therapy (HR = 0.74, 95% CI: 0.54-1.02, P = .066), although the difference did not reach statistical significance ( Figure 2 ).

In addition, although the difference was not statistically significant, patients with <3 brain metastases showed a favorable trend toward longer OS compared with those with ≥3 lesions (33.9% vs. 29.7%, p = 0.066).

A favorable trend in 2 behavioral measures (irritability, p = 0.066; aberrant motor behavior, p = 0.068) was noted in the active group.

After PSM, OS remained nonsignificant (P = 0.202), whereas DFS showed a favorable trend toward improvement in the nivolumab group, with 1-year DFS rates of 75.0% versus 68.8% and 3-year DFS rates of 68.2% versus 19.3%, respectively (P = 0.067).

It was noted though, that there was a favorable trend ( P = 0.07) for improvement in the PRP group in patients who presented with low-grade articular degeneration of the knee (Kellgren–Lawrence < 3) compared with the HA treatment group.

Consistent with our original report, there was a favorable trend to improved OS with melanoma cognate help (HR 0.64, 95% CI: 0.40–1.04, P = 0.07, Addendum Figure 1A; original report: HR 0.65, 95% CI: 0.40–1.05, P = 0.08), with delayed separation of the curves starting at 2.5 years and progressive widening of the curves such that the OS estimate for the 12MP + 6MHP regimen exceeded the upper bound of the 95% CI of the OS estimate for the 12MP+tet regimen at 8 years (Addendum Figure 1B).

p53 expression and AFTV efficacy AFTV therapy showed significantly greater efficacy in p53-negative cases, particularly with respect to overall survival ( p = 0.03), while progression-free survival showed a favorable trend ( p = 0.07).

A favorable trend toward reduced postoperative pneumonia incidence was observed (OR = 0.64, 95% CI: 0.39 to 1.03; p = 0.07).